Business
Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company
The new branding showcases the Company's innovative vision for the future and mission to redefine the retina experience BEDFORD, Mass., June 26, 2025
About this update from Ocular Therapeutix, Inc.
[{"type":"text","content":"The new branding showcases the Company's innovative vision for the future and mission to redefine the retina experience\nBEDFORD, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, announced the launch of its new corporate branding and website today, marking the next milestone of the Company's transformation to a retina-focused company. Ocular Therapeutix Logo Designed with visual accessibility at its core, the logo is science-based, transformative, and joyful. The circular “O” represents the eye and the retina, while the full-spectrum color palette captures the vibrancy of human vision and the richness of life it enables. The treatment of the “X” represents the intersection of where the company has been and where it is going. “Retinal disease, including wet age-related macular degeneration (AMD), remains a leading cause of blindness due to the high burden and pulsatile nature of available treatments,” said Pravin U. Dugel, MD, Executive Chairman, President, and CEO of Ocular Therapeutix. “At Ocular, we aim to redefine the retina experience to reduce that burden in hopes of preserving vision for the long-term. Our new branding reflects the meaningful progress we’ve made, driven by the momentum of our SOL trials and our commitment to patients.” Ocular Therapeutix Anthem Video Ocular Therapeutix: Retina Experience Redefined A Media Snippet accompanying this announcement is available in this link. Ocular’s top priority is to disrupt retinal disease treatment paradigms, starting with wet AMD which affects 1.8 million people in the U.S. alone. Current treatment options may require up to 12 injections per year, creating a heavy burden on patients and care partners that can lead to treatment discontinuation and poor long-term outcomes. With today’s pulsatile treatments, one in four patients develop fibrosis within two years and atrophy within five years. Ocular Therapeutix’ investigational therapy, AXPAXLI™ (also known as OTX-TKI), is an axitinib hydrogel administered by intravitreal injection that has the potential to dramatically improve durability and long-term outcomes for patients with wet AMD and other retinal diseases. The new corporate branding is now live across Ocular’s website, social media channels, and i...